Abstract
The development of levodopa therapy for Parkinson’s disease (PD) has spawned substantive clinical and scientific gains related to the experimental therapeutics of neurodegenerative disorders. Levodopa therapy has resulted in symptomatic benefit and increased life expectancy for the majority of PD patients. The rational development of levodopa therapy and related therapies to rectify the consequences of reduced dopaminergic neurotransmission in PD has also served as a prototype for the experimental therapeutics of other neurologic disorders associated with neurotransmitter deficits. In spite of these advances, the clinical and scientific limitations of replacement therapies have become increasingly evident. Symptomatic anti-PD benefits have proved transient, and clinical features intensify eventually in the setting of progressive neuronal degeneration. Disabling adverse effects, such as mental status disturbances, involuntary movements, and autonomic instability, further preclude or limit the use of dopaminergic therapies. The application of rational replacement therapy to other neurologic disorders has been constrained by the progressive and often multiple transmitter disturbances arising from neurode-generation.
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Ambani LM, Van Woert WH, Murphy S (1975) Brain peroxidase and catalase in Parkinson’s disease. Arch Neurol 32: 114–118
Aquilonius SM, Hartvig P (1986) Utilization of antiparkinson drugs in Sweden 1977–1984 (abstr). Ups J Med Sci [Suppl] 43: 93
Backlund EO, Granberg PO, Hamberger B, Knutsson E, Martensson A, Sedvall G, Sciger A, Olson L (1985 a) Transplantation of adrenal medullary tissue to striatum in parkinsonism: first clinical trials. J Neurosurg 62: 169–173
Backlund EO, Granberg PO, Hamberger B, Sedvall G, Sciger A, Olson A ( 1985 b) Transplantation of adrenal medullary tissue to striatum in parkinsonism. In: Bjorklund A, Stenevi U (eds) Neural grafting in the mammalian CNS. Elsevier, Amsterdam, pp 551–556
Ballard PA, Tetrud JW, Langston JW (1985) Permanent human parkinsonism due to l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine (MPTP): seven cases. Neurology (NY) 35: 949–956
Bannon MJ, Goedert M, Williams B (1984) The possible relation of glutathione, melanin, and l-methyl-4-phenyl-l,2,5,6-tetrahydropyridine ( MPTP) to Parkinson’s disease. Biochem Pharmacol 33: 2697–2698
Barbeau A, Roy M, Langston JW (1985 a) Neurological consequence of industrial exposure to l-methyl-4-phenyl-l,2,5,6-tetrahydropyridine. Lancet 1: 747
Barbeau A, Roy M, Paris S, Cloutier T, Plasse L, Poirier J (1958 b) Ecogentics of Parkinson’s disease: 4-hydroxylation of debrisoquine. Lancet 11: 1213–1216
Barbeau A, Roy M, Cloutier T, Plasse L, Paris S (1987) Environmental and genetic factors in the etiology of Parkinson’s disease. Adv Neurol 45: 299–306
Birkmayer W, Knoll J, Riederer P, Youdim MBH (1983) Deprenyl leads to prolongation of L-dopa efficacy in Parkinson’s disease. Mod Probl Pharmacopsychiatry 19: 170–176
Birkmayer W, Knoll J, Riederer P, Youdim MBH, Hars V, Marton J (1985) Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson’s disease: a longterm study. J Neural Trans 64: 113–127
Bjorklund A, Stenevi U (1979) Reconstruction of the nigrostriatal dopamine pathway by intracerebral nigral transplants. Brain Res 177: 555–560
Calne DB (1970) Parkinsonism: physiology, pharmacology and treatment. Williams and Wilkins, Baltimore
Calne DB, Langston JW, Martin WRW et al. (1985) Positron emission tomography after MPTP: observations relating to the cause of Parkinson’s disease. Nature 317: 246–248
Calne DB, Eisen A, McGeer E, Spencer P (1986) Alzheimer’s disease, Parkinson’s disease, and motorneuron disease: abiotropic interactions between aging and environment? Lancet 11: 1067–1070
Chiba K, Trevor A, Castagnoli N (1984) Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem Biophys Res Commun 120: 574–578
Cohen G (1983) The pathobiology of Parkinson’s disease: biochemical aspects of dopamine neuron senescence. J Neural Transm [Suppl] 19: 89–103
Cohen G (1985) Oxidative stress in the nervous system. In: Sies H (ed) Oxidative stress. Academic, London, pp 383–402
Cohen G, Pasik P, Cohen B, Leist A, Mytilineou C, Yahr MD (1984) Pargyline and deprenyl prevent the neurotoxicity of MPTP in monkeys. Eur J Pharmacol 106: 209–210
Cote LJ, Kremzner LT (1983) Biochemical changes in normal aging in human brain. Adv Neurol 38: 19–30
Cox DR (1972) Regression models and life tables. JR Statist Soc B 34: 187–220
Cox DR, Oakes D (1983) The analysis of survial data. Chapman and Hall, New York
Csanda E, Tarczy M (1983) Clinical evaluation of deprenyl (selegiline) in the treatment of Parkinson’s disease. Acta Neurol Scand [Suppl] 95: 117–122
D’Amato RJ, Lipman ZP, Snyder SH (1986) Selectivity of the parkinsonian neurotoxin MPTP: toxic metabolite MPP+ binds to neuromelanin. Science 231: 987–989
Dexter D, Carter C, Agid F, Agid Y, Lees AJ, Jenner P, Marsden CD (1986) Lipid peroxidation as cause of nigral death in Parkinson’s disease. Lancet 11: 639–640
Drucker-Colin R, Madrazo I, Diaz V, Torres C (in press) Open microsurgical autograft of adrenal medulla to caudate nucleus of patients with Parkinson’s disease: report of 8 cases. In: Gash DM, Sladek JR (eds) Transplantation in the mammalian CNS: preclinical and clinical studies. Prog Brain Res 73
Eisler T, Calne DB, Ebert MH, Kopin IJ, Ziegler MG, Levine R, Murphy DL (1975) Biochemical measurements during (-)-deprenyl treatment of parkinsonism. In: Sincer T, Van Korff R, Murphy DL (eds) Monoamine oxidase: structure, function and altered functions. Academic, New York, pp 497–505
Fahn S, Bressman SB (1984) Should levodopa therapy for parkinsonism be started early or late? Evidence against early treatment. Can J Neurol Sci 11: 200–206
Fleiss JL (1981) Statistical methods for rates and proportions, 2nd edn. Wiley, New York (table 6A.3)
Forno LS, Langston JW, DeLanney Le, Irwin I, Ricaurte GA (1986) Locus ceruleus lesions and eosinophilic inclusions in MPTP-treated monkeys. Ann Neurol 20: 449–455
Freed WJ, Olson L, Ko GN, Morihisa JM, Niehoff D, Stromberg I, Kuhar M Hoffer BJ, Wyatt RJ (1985) Intraventricular substantia nigra and adrenal medulla grafts: mechanisms of action and [3H] spirogeridol autoradiography. In: Bjorklund A, Stenevi U (eds) Neural grafting in the mammalian CNS. Elsevier, Amsterdam, pp 471–489
Goetz CG, Shannon KM, Carroll S, Klawans HL (1986) Progression of Parkinson’s disease in patients not treated with levodopa, (abstr). Ann Neurol 20: 148
Graham DG (1984) Catecholamine toxicity: a proposal for the molecular pathogenesis of manganese neurotoxicity and Parkinson’s disease. Neurotoxicology (Park Forest II ) 5: 83–96
Gupta M, Gupta BK, Thomas R, Bruemmer V, Sladek JR, Felten DL (1986) Aged mice are more sensitive to l-methyl-4-phenyl-l,2,5,6-tetrahydropyridine treatment than young adults. Neurosci Lett 70: 326–331
Heikkila RE, Manzino L, Cabbat RS, Duvoisin RC (1984) Protection against the dopaminergic neurotoxicity of l-methyl-4-phenyl-l,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 311: 467–469
Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression, and mortality. Neurology (NY) 17: 427–442
Johnson G (1976) Studies of the mechanisms of 6-hydroxydopamine cytotoxicity. Med Biol 54: 406–420
Kish SJ, Morito C, Hornykiewicz O (1985) Glutathione peroxidase activity in Parkinson’s disease brain. Neurosci Lett 58: 343–346
Kitt CA, D’Amato RJ, Alexander CM, Schwartzman RJ, Compton AL, Joh TH, Snyder SH, Price DL (1986) Effects of chloroquine on the neurotoxicity of MPTP in monkey. Soc Neurosci Abstr 12: 209
Langston JW, Ballard PA (1983) Parkinson’s disease in a chemist working with 1-methyl-4-phenyl-l,2,5,6-tetrahydropyridine. N Engl J Med 309: 310
Langston JW, Ballard P, Tetrud JW, Irwin I (1983) Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219: 979–980
Langston JW, Irwin I, Langston EB (1984 a) Pargyline prevents MPTP-induced parkinsonism in primates. Science 225: 1480–1482
Langston JW, Langston EB, Irwin I (1984b) MPTP-induced parkinsonism in human and non-human primates—clinical and experimental aspects. Acta Neurol Scand 70 (Suppl 100): 49–54
Madrazo I, Drucker-Colin R, Dfaz-Simental V, Torres C (1986) Open microsurgical autograft of adrenal medulla to the right caudate nucleus in human intractable Parkinson’s disease. Soc Neurosci Abstr 12: 563
Mann DMA, Yates PO (1947) Lipoprotein pigments: their relationship to aging in the human nervous system. II. The melanin content of pigmented nerve cells. Brain 97: 489–498
Martilla RJ (1983) Diagnosis and epidemiology of Parkinson’s disease. Acta Neurol Scand [Suppl] 95: 9–17
McGeer PL, McGeer EG, Suzuki JS (1977) Aging and extrapyramidal function. Arch Neurol 34: 33–35
McNeill TH, Koek LL, Haycock JW, Gash DM (1986) Glutathione reduction mimics MPTP neurotoxicity and age-correlated changes in dopamine neurons in substantia nigra of the C57BL/6NNia mouse. Soc Neurosci Abstr 12: 1470
Morihisa JM, Nakamura RK, Freed WJ, Mishkin M, Wyatt RJ (1984) Adrenal medulla grafts survive and exhibit catecholamine-specific fluorescence in the primate brain. Exp Neurol 84: 643–653
Perlow MJ, Freed WJ, Hoffer BJ, Sciger A, Olson L, Wyatt RJ (1979) Brain grafts reduce motor abnormalities produced by destruction of nigrostriatal dopamine system. Science 204: 643–647
Perry TL, Yong VW (1986) Idiopathic Parkinson’s disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients. Neurosci Lett 67: 269–274
Quinn N, Critchley P, Parkes D, Marsden CD (1986) When should levodopa be started? Lancet 11: 985–986
Rajput AH, Offord KP, Beard CM, Kurland LT (1984) Epidemiology of parkinsonism: incidence, classification and mortality. Ann Neurol 16: 278–282
Redmond DE, Sladek JR, Roth RH, Collier TJ, Elsworth JD, Deutch AY, Haber S (1986) Fetal neuronal grafts in monkeys given methylphenyltetrahydropyridine. Lancet 1: 1125–1127
Riederer P, Jellinger K, Seemann D (1984) Monoamine oxidase and parkinsonism. In: Tipton KF, Dostert P, Benedetti MS (eds) Monoamine oxidase and disease. Academic, New York, pp 403–415
Robinson DS (1975) Changes in monoamine oxidase and monoamines with human development and aging. Fed Proc 34: 103–107
Scheinberg IH, Sternlieb I (1984) Wilson’s disease. Saunders, Philadelphia
Schwab RS, England AC (1969) Projection technique for evaluating surgery in Parkinson’s disease. In: Gillingham FJ, Donaldson MC (eds) Third symposium on Parkinson’s disease. Livingston, Edinburgh, pp 152–157
Schwarcz R, Shoulson I (1987) Excitotoxins and Huntington’s disease. In: Coyle JT (ed) Experimental models of dementing disorders: a synaptic neurochemical approach. Liss, New York, pp 39–68
Shoulson I (1983) Huntington’s disease: anti-neurotoxic therapeutic strategies. In: Fuxe K, Roberts P, Schwarcz R (eds) Excitotoxins, (Wenner-Gren symposium series). MacMillan, New York, pp 343–353
Shoulson I, The Parkinson Study Group (1987) Correlates of clinical decline in early Parkinson’s disease (abstr). Neurology 37 (Suppl 1): 278
Shou-Shu J, Wa-Cheng Z, Minh-Chen D, Jia-Bang S (in press) The clinical study of adrenal medullary tissue transplantation to striatum in parkinsonism. In: Gash DM, Sladek JR (eds) Transplantation in the mammalian CNS: preclinical and clinical studies. Prog Brain Res 73
Slivka A, Cohen G (1985) Hydroxyl radical attack on dopamine. J Biol Chem 260: 15 466–15
Snyder SH, D’Amato RJ (1986) MPTP: a neurotoxin relevant to the pathophysiology of Parkinson’s disease. Neurology 36: 250–258
Stampfer MJ, Buring JE, Wilett W, Rosner B, Eberlein K, Hennekens CH (1985) The 2x2 factorial design: its application to a randomized trial of aspirin and carotene in U.S. physicians. Stat Med 4: 111–116
Tanner CM (1986) Influence of environmental factors on the onset of Parkinson’s disease (abstr). Neurology 36 (Suppl 1): 215
Tetrud J, Langston WJ (1986) Early parkinsonism in humans due to MPTP exposure. Neurology 36 (Suppl 1): 308
Van Woert MH, Ambani LM (1974) Biochemistry of neuromelanin. Adv Neurol 5: 215–222
Vyas I, Heikkila RE, Nicklas WJ (1986) Studies on the neurotoxicity of MPTP. Inhibition of NAD-linked substrate oxidation by its metabolite, MPP+. J Neurochem 46: 1501–1507
Wooten GF (1984) Parkinsonism. In: Pearlman AL, Collins RC (eds) Pathophysiology, 3rd ed. Oxford University Press, New York, pp 365–377
World Almanac (1986) Disability insurance benefits and wage earning. Newspaper Enterprise, New York, pp 68–72, 114
Wright JM, Wall RA, Perry TL, Paty DW (1983) Chronic parkinsonism secondary to intranasal administration of a product of meperidine-analogue synthesis. N Engl J Med 310: 325
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1989 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Shoulson, I. (1989). Experimental Therapeutics Directed at the Pathogenesis of Parkinson’s Disease. In: Calne, D.B. (eds) Drugs for the Treatment of Parkinson’s Disease. Handbook of Experimental Pharmacology, vol 88. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-73899-9_11
Download citation
DOI: https://doi.org/10.1007/978-3-642-73899-9_11
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-73901-9
Online ISBN: 978-3-642-73899-9
eBook Packages: Springer Book Archive